Vivos Therapeutics, Inc., a healthcare company based in Littleton, Colorado, is making significant strides in the development and commercialization of innovative treatments for sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA).
Founded on July 7, 2016, by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman, Vivos Therapeutics has focused its mission on providing non-invasive and effective alternatives to traditional therapies for patients struggling with breathing-related sleep conditions. These conditions, particularly obstructive sleep apnea, affect millions of individuals worldwide and have been linked to serious health issues such as cardiovascular disease, diabetes, and chronic fatigue.
The company’s approach combines advanced medical technologies with a patient-centered treatment model. Rather than relying solely on CPAP machines, which can be uncomfortable and have low patient compliance rates, Vivos offers oral appliance therapy and related diagnostic and therapeutic services. These custom-designed devices aim to correct anatomical deficiencies in the airway, providing a long-term solution rather than a temporary fix.
Vivos’s growing network of trained healthcare professionals across North America helps ensure that patients receive personalized care tailored to their specific condition. The company’s commitment to research and innovation allows it to continuously improve its technology and treatment methods, contributing to better clinical outcomes.
Recently, Vivos Therapeutics’ stock was priced at $3.70, reflecting a 2.78% increase. This market activity signals investor interest in the company’s progress and the broader potential of its technology within the sleep health sector.
With its headquarters in Colorado and a firm foundation built by experienced founders, Vivos continues to position itself at the forefront of sleep medicine. The company’s dedication to advancing health outcomes for those with sleep-disordered breathing reinforces its role as a promising leader in the medical technology industry.